Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1813 - Long-term Adverse Effects (AEs) after dose-escalation with High-Dose Rate Brachytherapy in combination with External Beam Radiation Therapy (BT/RT). Comparison to External Beam Radiation Therapy alone (RT)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Genitourinary Cancers

Presenters

Trude Wedde

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

T.B. Wedde, S.D. Fosså, A. Dahl, M. Schulz, W. Lilleby

Author affiliations

  • Oncology, Oslo University Hospital, 0424 - Oslo/NO
More

Resources

Abstract 1813

Background

Few studies have compared long-term patient reported AEs of men with Prostate Cancer (PCa) treated with dose-escalation by means of BT/RT to RT (70-78 Gy) alone. In this study, we compare AEs and quality of life (QoL) between these two treatment modalities.

Methods

259 eligible men from the BT/RT cohort (2004-2011) and 123 patients (2009-2010) from a RT cohort assessed their AEs and QoL by questionnaires a minimum of 5 years after treatment. Hormonal therapy was given for 1-2 years. EPIC-26 covered urinary, sexual and bowel function and bother. The hormone domain was excluded. The SF-12 questionnaire covered QoL. The scores ranged from 0 (worst) to 100 (best). Clinical significance was set to a score difference > 10 points. Statistical significance was evaluated by Student t-test with significance level p < 0.05. Chronic fatigue was reported as percentage.

Results

Median age at survey was 74 years for both cohorts. The EPIC-26 and SF12 scores for the above domains were similar in the two cohorts with no clinical or statistical significance (Table). Chronic fatigue was higher after treatment with RT compared BT/RT, although not significantly.Table: 853P

MeasureBT/RT Mean (SD)RT Mean (SD)P value
Sexual function27.9 (29.5) n = 25520.8 (24.3) n = 1200.06
Sexual bother48.2 (37.5) n = 25445.9 (34.7) n = 1210.56
Urinary function83.6 (18.0) n = 25880.1 (20.5) n = 1230.10
Urinary irritation/obstruction81.3 (19.6) n = 24981.8 (16.8) n = 1130.80
Urinary incontinence88.7 (18.1) n = 25885.0 (22.5) n = 1230.11
Urinary bother79.9 (26.5) n = 25777.6 (30.0) n = 1230.47
Bowel function86.7 (20.6) n = 25483.1 (21.7) n = 1210.12
Bowel bother83.0 (25.1) n = 25880.4 (26.7) n = 1210.34
PCS12 (SF12)46.4 (10.5) n = 22445.1 (10.1) n = 1010.30
MCS12 (SF12)53.6 (8.0) n = 22452.7 (9.2) n = 1010.38
Chronic fatigue22.0% n = 19927.1% n = 860.28

Conclusions

Dose-escalation by means of BT/RT does not increase the AEs reported for the urinary, bowel and sexual domains of EPIC-26 or health-related QoL. Hence, BT/RT is a good treatment option for eligible patients.

Clinical trial identification

Legal entity responsible for the study

Wolfgang Lilleby.

Funding

Raagholt Foundation, Bergersen Foundation, Eckbo Foundation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.